Literature DB >> 31061837

The Parkinson's Disease Sleep Scale-2 (PDSS-2): Validation of the Spanish Version and Its Relationship With a Roommate-Based Version.

Pablo Martinez-Martin1,2, John B Wetmore1, Carmen Rodríguez-Blázquez1,2, Tomoko Arakaki3, Oscar Bernal4, Victor Campos-Arillo5, Christopher Cerda6, Ingrid Estrada-Bellmann6, Nélida Garretto3, Letty Ginsburg7, Jorge Uriel Máñez-Miró8, Juan Carlos Martínez-Castrillo9, Ivonne Pedroso10, Marcos Serrano-Dueñas11, Carlos Singer7, Mayela Rodríguez-Violante12, Francisco Vivancos8.   

Abstract

BACKGROUND: Because of the prevalence and impact of sleep disorders in Parkinson's disease (PD), valid instruments for their evaluation and monitoring are necessary. However, some nocturnal sleep disorders may go unnoticed by patients themselves.
OBJECTIVES: To validate a pan-Spanish version of the Parkinson's Disease Sleep Scale Version 2 (PDSS-2) and to test the relationships between the PDSS-2 and a PDSS-2 roommate version.
METHODS: PD patients (n = 399) from seven Spanish-speaking countries were included. In addition to the tested PDSS-2 scales, valid measures for sleep disorders and both motor and nonmotor manifestations were applied. Acceptability, dimensionality, reliability, precision, and construct validity were explored, as well as discrepancies and agreement between the PDSS-2 and the roommate version.
RESULTS: PDSS-2 showed negligible floor and ceiling effects. Four factors (57% of the variance) were identified. Reliability parameters were satisfactory: alpha = 0.84; item homogeneity coefficient = 0.27; corrected item total correlation = 0.28 to 0.61; and test-retest reliability (average kappa = 0.70; intraclass correlation coefficient [ICC] = 0.83). The standard error of measurement was 5.84, and correlations with other scales assessing nocturnal sleep were high (rS = 0.62-0.56). In comparison to the patient-based total score, the by proxy total score showed no significant difference, high correlation (rS = 0.70), and acceptable agreement (ICC = 0.69), but there were discrepancies in two or more points in 18% of item scores.
CONCLUSIONS: The Spanish version of the PDSS-2 has shown satisfactory clinimetric attributes. Acceptability and precision data are presented for the first time. The PDSS-2 roommate version could be useful to complement the patient-based evaluation, but additional studies are needed.

Entities:  

Keywords:  PDSS‐2; PDSS‐2 Roommate version; Parkinson's disease; Spanish version; clinimetric properties

Year:  2019        PMID: 31061837      PMCID: PMC6476589          DOI: 10.1002/mdc3.12749

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  48 in total

1.  Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life.

Authors:  K W Wyrwich; W M Tierney; F D Wolinsky
Journal:  J Clin Epidemiol       Date:  1999-09       Impact factor: 6.437

Review 2.  Assessing health status and quality-of-life instruments: attributes and review criteria.

Authors:  Neil Aaronson; Jordi Alonso; Audrey Burnam; Kathleen N Lohr; Donald L Patrick; Edward Perrin; Ruth E Stein
Journal:  Qual Life Res       Date:  2002-05       Impact factor: 4.147

Review 3.  Identifying meaningful intra-individual change standards for health-related quality of life measures.

Authors:  K W Wyrwich; F D Wolinsky
Journal:  J Eval Clin Pract       Date:  2000-02       Impact factor: 2.431

Review 4.  Parkinson's disease and sleep.

Authors:  Diego Garcia-Borreguero; Oscar Larrosa; Mauricio Bravo
Journal:  Sleep Med Rev       Date:  2003-04       Impact factor: 11.609

5.  Fatigue in patients with Parkinson's disease.

Authors:  K Karlsen; J P Larsen; E Tandberg; K Jørgensen
Journal:  Mov Disord       Date:  1999-03       Impact factor: 10.338

6.  Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study.

Authors:  E Tandberg; J P Larsen; K Karlsen
Journal:  Mov Disord       Date:  1999-11       Impact factor: 10.338

7.  A comparison of health utility measures for the evaluation of multiple sclerosis treatments.

Authors:  J D Fisk; M G Brown; I S Sketris; L M Metz; T J Murray; K J Stadnyk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

8.  A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA.

Authors:  J Marinus; M Visser; A M Stiggelbout; J Martin Rabey; P Martínez-Martín; U Bonuccelli; P H Kraus; J J van Hilten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

9.  Assessment of sleep and sleepiness in Parkinson disease.

Authors:  Johan Marinus; Martine Visser; Jacobus Johannes van Hilten; Gert Jan Lammers; Anne Margarethe Stiggelbout
Journal:  Sleep       Date:  2003-12-15       Impact factor: 5.849

Review 10.  Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.

Authors:  J C Hobart; A Riazi; D L Lamping; R Fitzpatrick; A J Thompson
Journal:  Health Technol Assess       Date:  2004-03       Impact factor: 4.014

View more
  3 in total

1.  Prevalence and profile of nocturnal disturbances in Chinese patients with advanced-stage Parkinson's disease: a cross-sectional epidemiology study.

Authors:  Guiying He; Chun-Feng Liu; Qinyong Ye; Zhenguo Liu; Miao Jin; Huifang Shang; Ling Chen; Houzhen Tuo; Hong Jiang; Jifu Cai; Kalpesh Joshi; James Cooper; Lu Zi; Shengdi Chen
Journal:  BMC Neurol       Date:  2021-05-12       Impact factor: 2.474

2.  Validity and Reliability of the Persian Version of Parkinson's Disease Sleep Scale-2.

Authors:  Mohammad Taghi Joghataei; Seyed-Mohammad Fereshtehnejad; Maryam Mehdizadeh; Sepideh Goudarzi; Sayed Amir Hasan Habibi; Mahsa Meimandi; Arian Dehmiyani; Ghorban Taghizadeh
Journal:  Parkinsons Dis       Date:  2021-12-20

Review 3.  Personalized Assessment of Insomnia and Sleep Quality in Patients with Parkinson's Disease.

Authors:  Ştefania Diaconu; Cristian Falup-Pecurariu
Journal:  J Pers Med       Date:  2022-02-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.